In biotechnology, where uncertainty is inherent and data constantly evolve, the ability to know when to persist with an idea and when to pivot can determine the success or failure of a program. Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, has spent more than three decades navigating this challenge across academia, startups, and R&D leadership. His career—spanning professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as CSO at Sigilon Therapeutics, and advising through Flagship Pioneering—has given him a unique perspective on why this issue matters now, as the pace of scientific discovery accelerates and the pressure to deliver results intensifies.
Ashton-Rickardt emphasizes that commitment to an idea can easily become attachment, clouding judgment. "You have to separate attachment to the idea from attachment to the problem," he says. "If the problem is important, there may be several ways to approach it." This distinction is critical in biotech, where a promising hypothesis may need to be adjusted or abandoned as new data emerge. Changing course, he argues, is not an admission of failure but often evidence of learning. "Flexibility is important because changing your approach is not necessarily an admission that you failed," he notes. "Sometimes it is evidence that you learned something."
The implications for scientific leadership are profound. Leaders must provide direction without pretending to know the future, especially when researchers, executives, and investors demand decisions before all questions are answered. Ashton-Rickardt believes transparency about what is known, what remains uncertain, and what would trigger a change in course can strengthen confidence rather than weaken it. When teams understand that new information is expected to influence decisions, they are more willing to raise concerns and challenge assumptions. "There is a difference between providing direction and pretending to know the future," he says. "In biotech, there are simply too many unknowns."
Curiosity also remains essential at the top. Ashton-Rickardt’s own journey—from a working-class family in the UK to academic science and then back to Boston to start a biotech company—has required him to constantly learn new environments. He values colleagues who ask good questions, even when those questions complicate the project. "The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated," he says. Leaders should admit what they do not know, and strong scientific thinking is often reflected in the ability to explain what evidence would change one’s mind.
At BE Therapeutics and Halyard Therapeutics, where he is co-founder and CSO, Ashton-Rickardt focuses on engineered cell therapies and treatments for neurological and other serious diseases. Translating complex science into viable programs requires conviction, but conviction must remain tied to evidence. "The goal is not to prove that your first idea was right," he says. "The goal is to solve an important problem." This mindset can shape everything from experimental design to resource allocation, making organizations more adaptable in an era of rapid therapeutic innovation.
As new tools and data continue to reshape what is possible, Ashton-Rickardt’s insights underscore a fundamental truth: the best scientific leaders are those who can balance steadfastness with flexibility, fostering a culture where learning and adaptation are valued over ego. His perspective offers a timely reminder that in science, the willingness to change course may be the ultimate sign of strength.
